Actively Recruiting
Phase II Study of High Dose Radiation Therapy After Initial Chemotherapy for Treating Locally Advanced Pancreatic Cancer
Led by University Health Network, Toronto · Updated on 2026-04-16
43
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of high-dose radiation therapy in patients with locally advanced pancreatic cancer who have responded to initial chemotherapy. This Phase II clinical trial aims to determine whether this radiation treatment can improve outcomes, quality of life, or overall survival rates for these patients. The study is sponsored by the University Health Network, Toronto, and focuses on patients whose cancer has remained stable or decreased in size after chemotherapy. Participants will receive high-dose radiation therapy delivered in fractions over set periods, such as 50 Gray over 5 sessions every other day in 2 weeks, 67.5 Gray over 15 sessions daily in 3 weeks, or 75 Gray over 25 sessions daily in 5 weeks. The specific radiation dose and schedule will be determined by the radiation oncologist based on each participants condition. An optional tumor biopsy may be performed before treatment. During the study, participants will complete quality of life questionnaires and donate blood samples for research. Researchers will monitor overall survival over 5 years as the primary outcome. Participants must be able to give informed consent and will be followed closely to assess treatment effects and safety. The study will begin in March 2025 and continue through April 2030.
CONDITIONS
Brief Title
A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment
Research Team
A
Anna Dodd
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
